Prognostic value of systemic immune-inflammation index in patients with advanced non-small-cell lung cancer. (11th May 2018)

• Record Type: Journal Article
• Authors: Guo, Dong; Zhang, Jinbao; Jing, Wang; Liu, Jiafeng; Zhu, Hui; Fu, Lei; Li, Minghuan; Kong, Li; Yue, Jinbo; Yu, Jinming
• Is Part Of: Future oncology. Volume 14:Number 25(2018)
• Page Start: 2643
• Page End: 2650
• Publication Date: 2018-05-11
• Subjects: advanced -- non-small-cell lung cancer -- prognostic -- systemic immune-inflammation index; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2018-0285
• Languages: English
• ISSNs: 1479-6694

Abstract

Aim: We aimed to investigate the association between systemic immune-inflammation index (SII) and the clinical outcomes in patients with advanced non-small-cell lung cancer.Materials & methods: The SII was calculated as platelet (P) × neutrophil (N)/lymphocyte (L), and the data were obtained within 1 week before treatment. Kaplan–Meier analysis and Cox proportional hazard models were used to assess the prognostic value of SII.Results: Kaplan–Meier analyses revealed that the higher SII group was associated with poorer progression-free survival (p < 0.001) and poorer overall survival (p < 0.001). Multivariable Cox analysis further revealed SII as an independent prognostic factor for overall survival (p = 0.010) and progression-free survival (p = 0.001).Conclusion: SII can serve as a useful biomarker to predict recurrence and death for patients with advanced non-small-cell lung cancer.